19 hours ago · BioMarin Pharmaceutical said on ⁠Friday it would acquire Amicus ‍Therapeutics ‍for about $4.8 ‍billion, expanding its presence in rare metabolic diseases.

19 hours ago · BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, in the drugmaker's second deal this year to expand its presence in rare …

16 hours ago · BioMarin has pulled off its largest transaction in the company’s 28-year history, ponying up $4.8 billion for fellow rare disease specialist Amicus.

19 hours ago · BioMarin Pharmaceutical Inc. agreed to buy Amicus Therapeutics Inc. for about $4.8 billion to expand its portfolio of treatments for rare diseases.

19 hours ago · BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn of the century.

19 hours ago · BioMarin (BMRN) stock is in focus as the company agrees to acquire rare disease drug developer Amicus Therapeutics (FOLD) for $4.8B in cash. Read more here.

17 hours ago · BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease …

The meaning of AMICUS is amicus curiae.

17 hours ago · The acquisition will add two new treatments to BioMarin’s existing medicines for rare inherited metabolic disorders.

Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare …